Catherine Anne Rehm

Ms. Catherine Anne Rehm


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
GBGiorgio Bozzi
Giorgio Bozzi
FSF. R. Simonetti
F. R. Simonetti
SWS. A. Watters
S. A. Watters
EAElizabeth Anderson
Elizabeth Anderson
MGM. Gouzoulis
M. Gouzoulis
Frank MaldarelliFrank Maldarelli
Frank Maldarelli
Long-term persistence, not ongoing virus replication, is primarily responsible for maintaining HIV during antiretroviral therapy.

5 May 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
CGChristina Guzzo
Christina Guzzo
DIDavid Ichikawa
David Ichikawa
CPChung Park
Chung Park
DPDamilola Phillips
Damilola Phillips
QLQingbo Liu
Qingbo Liu
PLPaolo Lusso
Paolo Lusso
The intestinal mucosa is a key anatomical site for HIV-1 replication and CD4+ T cell depletion. Accordingly, in vivo treatment with an antibody to the gut-homing integrin α4β7 was shown to reduce viral transmission, delay disease progression, and induce persistent virus control in macaques challenged with simian immunodeficiency virus (SIV). We show that integrin α4β7 is efficiently incorporated into the envelope of HIV-1 virions. Incorporated α4β7 is functionally active as it binds mucosal addressin cell adhesion molecule–1 (MAdCAM-1), promoting HIV-1 capture by and infection of MAdCAM-expressing cells, which in turn mediate trans-infection of bystander cells. Functional α4β7 is present in circulating virions from HIV-infected patients and SIV-infected macaques, with peak levels during the early stages of infection. In vivo homing experiments documented selective and specific uptake of α4β7+ HIV-1 virions by high endothelial venules in the intestinal mucosa. These results extend the paradigm of tissue homing to a retrovirus and are relevant for the pathogenesis, treatment, and prevention of HIV-1 infection.

25 January 2020 in Viruses
Verified
Journal Article
Open access
PDF file
EAElizabeth Anderson
Elizabeth Anderson
FSFrancesco R. Simonetti
Francesco R. Simonetti
RGRobert Gorelick
Robert Gorelick
SHShawn Hill
Shawn Hill
MGMonica A. Gouzoulis
Monica A. Gouzoulis
Frank MaldarelliFrank Maldarelli
Frank Maldarelli
Combination antiretroviral therapy (cART) controls but does not eradicate HIV infection; HIV persistence is the principal obstacle to curing infections. The proportion of defective proviruses increases during cART, but the dynamics of this process are not well understood, and a quantitative analysis of how the proviral landscape is reshaped after cART is initiated is critical to understanding how HIV persists. Here, we studied longitudinal samples from HIV infected individuals undergoing long term cART using multiplexed Droplet Digital PCR (ddPCR) approaches to quantify the proportion of deleted proviruses in lymphocytes. In most individuals undergoing cART, HIV proviruses that contain gag are lost more quickly than those that lack gag. Increases in the fraction of gag-deleted proviruses occurred only after 1–2 years of therapy, suggesting that the immune system, and/or toxicity of viral re-activation helps to gradually shape the proviral landscape. After 10–15 years on therapy, there were as many as 3.5–5 times more proviruses in which gag was deleted or highly defective than those containing intact gag. We developed a provirus-specific ddPCR approach to quantify individual clones. Investigation of a clone of cells containing a deleted HIV provirus integrated in the HORMAD2 gene revealed that the cells underwent a massive expansion shortly after cART was initiated until the clone, which was primarily in effector memory cells, dominated the population of proviruses for over 6 years. The expansion of this HIV-infected clone had substantial effects on the overall proviral population.

22 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
JYJun Yang
Jun Yang
MHMing Hao
Ming Hao
MKMuhammad A. Khan
Muhammad A. Khan
MRMuhammad T. Rehman
Muhammad T. Rehman
HHHelene C. Highbarger
Helene C. Highbarger
Tomozumi ImamichiTomozumi Imamichi
Tomozumi Imamichi
We have recently reported that a recombinant HIV-1NL4.3 containing Met-to-Ile change at codon 50 of integrase (IN) (IN:M50I) exhibits suppression of the virus release below 0.5% of WT HIV, and the released viral particles are replication-incompetent due to defects in Gag/GagPol processing by inhibition of the initiation of autoprocessing of GagPol polyproteins in the virions and leads to replication-incompetent viruses. The coexisting Ser-to-Asn change at codon 17 of IN or Asn-to-Ser mutation at codon 79 of RNaseH (RH) compensated the defective IN:M50I phenotype, suggesting that both IN and RH regulate an HIV infectability. In the current study, to elucidate a distribution of the three mutations during anti-retroviral therapy among patients, we performed a population analysis using 529 plasma virus RNA sequences obtained through the MiSeq. The result demonstrated that 14 plasma HIVs contained IN:M50I without the compensatory mutations. Comparing the sequences of the 14 viruses with that of the defective virus illustrated that only Val-to-Ile change at codon 151 of IN (IN:V151I) existed in the recombinant virus. This IN:V151I is known as a polymorphic mutation and was derived from HIVNL4.3 backbone. A back-mutation at 151 from Ile-to-Val in the defective virus recovered HIV replication capability, and Western Blotting assay displayed that the back-mutation restored Gag/GagPol processing in viral particles. These results demonstrate that a combination of IN:M50I and IN:V151I mutations, but not IN:M50I alone, produces a defective virus.

1 July 2016 in Journal of Virus Eradication
Verified
Journal Article
Open access
EAE. Anderson
E. Anderson
MGM. Gouzoulis
M. Gouzoulis
AGA. Ganesan
A. Ganesan
CRCatherine Anne Rehm
Catherine Anne Rehm
SJSara R Jones
Sara R Jones
Frank MaldarelliFrank Maldarelli
Frank Maldarelli

31 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CLChuen-Yen Lau
Chuen-Yen Lau
PGPia Gabrielle Gorme
Pia Gabrielle Gorme
NSNina Sharma
Nina Sharma
DKDanielle Konlian
Danielle Konlian
RDRobin Dewar
Robin Dewar
Frank MaldarelliFrank Maldarelli
Frank Maldarelli
HIV-2 infection results in progressive CD4 lymphopenia and death if untreated. The course of HIV-2 infection is more indolent than HIV-1, and the viral and immune mechanisms responsible for this slower pathogenesis are incompletely understood. Persistent inflammation with elevations in cellular and soluble markers of immune activation is a characteristic feature of HIV-2 infection and has been reported to be related to levels of HIV-infected cells in peripheral blood. Here we report an individual with HIV-2 who had persistently elevated levels of activated CD8 lymphocyte subsets that were significantly higher than those quantified in a set of controls without HIV matched for age, sex, and race. Despite elevated levels of immune activation, no detectable HIV-2 RNA or proviral DNA was present in blood. Without undergoing antiretroviral therapy, longitudinal analysis revealed this sustained immune activation was not associated with a progressive CD4 lymphopenia or evidence of disease complications. The presence of strong immune responses without detectable levels of HIV-2 nucleic acid complicates diagnostic testing for HIV-2, and highlights gaps in our understanding of HIV-2 pathogenesis.